NO981272L - Humanisert anti-human-Fas-antistoff - Google Patents
Humanisert anti-human-Fas-antistoffInfo
- Publication number
- NO981272L NO981272L NO981272A NO981272A NO981272L NO 981272 L NO981272 L NO 981272L NO 981272 A NO981272 A NO 981272A NO 981272 A NO981272 A NO 981272A NO 981272 L NO981272 L NO 981272L
- Authority
- NO
- Norway
- Prior art keywords
- humanized anti
- human fas
- fas antibody
- antibodies
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6793897 | 1997-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO981272D0 NO981272D0 (no) | 1998-03-20 |
NO981272L true NO981272L (no) | 1998-09-22 |
Family
ID=13359383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO981272A NO981272L (no) | 1997-03-21 | 1998-03-20 | Humanisert anti-human-Fas-antistoff |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0866131A3 (pt) |
KR (1) | KR19980080514A (pt) |
AR (1) | AR012148A1 (pt) |
AU (1) | AU736287B2 (pt) |
BR (1) | BR9800937A (pt) |
CA (1) | CA2232828A1 (pt) |
CZ (1) | CZ85898A3 (pt) |
HU (1) | HUP9800613A3 (pt) |
ID (1) | ID20065A (pt) |
IL (1) | IL123756A0 (pt) |
NO (1) | NO981272L (pt) |
NZ (1) | NZ330004A (pt) |
PL (1) | PL325457A1 (pt) |
TR (1) | TR199800517A3 (pt) |
ZA (1) | ZA982371B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
ATE391136T1 (de) * | 1998-06-18 | 2008-04-15 | Imed Ab | Fas peptide und antikörper zur modulierung von apoptosis |
AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
DK1143994T3 (da) * | 1999-01-11 | 2003-10-20 | Leadd Bv | Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme |
AU2004233486B2 (en) * | 1999-01-11 | 2007-09-13 | Leadd B.V. | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
CZ20014181A3 (cs) * | 1999-05-24 | 2002-03-13 | Sankyo Company Limited | Farmaceutický prostředek obsahující protilátku a pouľití protilátky |
AU2003215365A1 (en) | 2002-02-21 | 2003-09-09 | Duke University | Treatment methods using anti-cd22 antibodies |
AU2003234003A1 (en) * | 2002-05-17 | 2003-12-02 | Fusion Antibodies Limited | Treatment of cancer by the use of anti fas antibody |
GB0306618D0 (en) * | 2003-03-22 | 2003-04-30 | Univ Newcastle | Antibody |
EP1999148B8 (en) | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US8030026B2 (en) * | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
EP3374399A1 (en) | 2015-11-11 | 2018-09-19 | Opi Vi- IP Holdco LLC | Composition and methods for anti-tnfr2 antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
CA2174132A1 (en) * | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
CA2158822C (en) * | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
AU724579B2 (en) * | 1996-04-01 | 2000-09-28 | Sankyo Company Limited | Anti-Fas recombinant antibodies and DNA therefor |
-
1998
- 1998-03-19 IL IL12375698A patent/IL123756A0/xx unknown
- 1998-03-19 AU AU59375/98A patent/AU736287B2/en not_active Ceased
- 1998-03-19 ZA ZA982371A patent/ZA982371B/xx unknown
- 1998-03-20 HU HU9800613A patent/HUP9800613A3/hu unknown
- 1998-03-20 EP EP98302113A patent/EP0866131A3/en not_active Withdrawn
- 1998-03-20 CZ CZ98858A patent/CZ85898A3/cs unknown
- 1998-03-20 KR KR1019980009795A patent/KR19980080514A/ko not_active Application Discontinuation
- 1998-03-20 NO NO981272A patent/NO981272L/no unknown
- 1998-03-20 PL PL98325457A patent/PL325457A1/xx unknown
- 1998-03-20 ID IDP980403A patent/ID20065A/id unknown
- 1998-03-20 CA CA002232828A patent/CA2232828A1/en not_active Abandoned
- 1998-03-20 NZ NZ330004A patent/NZ330004A/xx unknown
- 1998-03-20 TR TR1998/00517A patent/TR199800517A3/tr unknown
- 1998-03-23 AR ARP980101321A patent/AR012148A1/es unknown
- 1998-03-23 BR BR9800937-0A patent/BR9800937A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL123756A0 (en) | 1998-10-30 |
EP0866131A2 (en) | 1998-09-23 |
AR012148A1 (es) | 2000-09-27 |
HUP9800613A3 (en) | 2001-04-28 |
TR199800517A2 (xx) | 1998-10-21 |
EP0866131A3 (en) | 1999-12-15 |
HUP9800613A2 (hu) | 1999-02-01 |
AU5937598A (en) | 1998-10-15 |
ID20065A (id) | 1998-09-24 |
PL325457A1 (en) | 1998-09-28 |
CA2232828A1 (en) | 1998-09-21 |
CZ85898A3 (cs) | 1998-10-14 |
BR9800937A (pt) | 2000-01-11 |
HU9800613D0 (en) | 1998-05-28 |
NO981272D0 (no) | 1998-03-20 |
NZ330004A (en) | 1998-10-28 |
ZA982371B (en) | 1998-09-28 |
AU736287B2 (en) | 2001-07-26 |
TR199800517A3 (tr) | 1998-10-21 |
KR19980080514A (ko) | 1998-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO981272L (no) | Humanisert anti-human-Fas-antistoff | |
IL263573A (en) | Anti-ngf antibodies and methods of using them | |
WO1996020277A3 (en) | Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen | |
EP0765172A4 (en) | FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES | |
IL172646A0 (en) | Antibodies against interleukin -22 and uses therefor | |
WO1998050433A3 (en) | Human monoclonal antibodies to epidermal growth factor receptor | |
EP0867451A3 (en) | Monoclonal antibodies reactive with defined regions of the T cell antigen receptor | |
AU3208397A (en) | Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same | |
RU2012102323A (ru) | Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента | |
DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
HK1011031A1 (en) | Recombinant anti-VLA4 antibody molecules | |
ES2165506T3 (es) | Antagonistas del il-8 para el tratamiento del asma. | |
MX9702422A (es) | Anticuerpos recombinantes contra fas y adn para los mismos. | |
AU1971799A (en) | Peptide epitopes recognised by antifilaggrin autoantibodies in serum from rheumatoid arthritis patients | |
DK1021200T3 (da) | Fremgangsmåder og præparater til behandling af rheumatoid arthritis | |
NO894555D0 (no) | Monoklonalt antistoff som spesifikt gjenkjenner n-glycolyl type gm2, hybridom som produserer antistoff og fremgangsmaate for fremstilling av hybridomet. | |
DK0610447T3 (da) | CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene | |
NO960683L (no) | Monoklonalt antistoff som gjenkjenner interstitialcelle-overflateantigen | |
AU6162794A (en) | Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor | |
IL161872A (en) | Antibody stimulating il-1ra production | |
UA109629C2 (uk) | Людське моноклональне антитіло проти cd20 | |
TH131300B (th) | ตัวแปรอิมมูโนกลูบูลินและการใช้สิ่งนั้น |